Non-interventional study on Guideline Directed Medical Therapy for patients with heart failure (HF) in Germany - PHRASE-HF

Study identifier:D1699R00045

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

PHenotype-based RApid SEquencing of guideline-directed medical therapy for Heart Failure with reduced ejection fraction (PHRASE-HF): A multicentre, prospective, non-interventional study to examine outcomes of rapid in-hospital implementation of GDMT and its translation from discharge into routine care

Medical condition

Heart Disease, heart failure

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

438

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Sept 2024
Estimated Primary Completion Date: 31 Dec 2026
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria